Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas

Inclusion Criteria

• •Has a histologically or cytologically documented advanced solid tumor or lymphoma that has relapsed from or is refractory to standard treatment, and for whom no standard treatment is available.
• •Man or woman \>= 18 years old.
• •Has an Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
• •Has adequate bone marrow function, defined as: Platelet count \>= 100 X 10\*9/L Hemoglobin level \>= 9.0 g/dL Absolute neutrophil count \>= 1.5 x 10\*9/L
• •Has adequate renal function, defined as: Creatinine clearance \>= 60 mL/minute, as calculated using the modified Cockroft Gault equation, (\[{140 - age in years} × {actual weight in kg}\] divided by \[{72 × serum creatinine in mg/dL} multiplied by 0.85 if female\]), OR creatinine \<= 1.5 X upper limit of normal (ULN)
• •Has adequate hepatic function, defined as: AST/ALT \<= 3 X ULN (if liver metastases are present, \<= 5 X ULN) Bilirubin \<= 1.5 X ULN
• •Has adequate blood clotting function, defined as: International normalized ratio and activated partial thromboplastin time \<= 1.5 X ULN
• •Subject should be able to provide written informed consent and comply with protocol visits and procedures.
• •Subject (male and female) of childbearing/ reproductive potential must agree to use double barrier contraceptive measures or avoid intercourse during the study and for 90 days after the last dose of study drug.
• •Subject must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects) and must sign and date an Institutional Review Board-approved Informed Consent Form (including Health Insurance Portability and Accountability Act authorization, if applicable) before performance of any study specific procedures or tests.
• •Is willing to provide pre-existing diagnostic or resected tumor samples, such as paraffin-embedded sections. Providing a fresh tumor biopsy sample is optional.
• •Following treatment-free period prior to enrollment to the study: i)Surgery: 4 weeks for major surgery (e.g., laparotomy and thoracotomy); 2 weeks for less extensive surgery (e.g., colostomy) ii)Radiation: 4 weeks (2 weeks for palliative irradiation to bone metastases \[except for pelvic irradiation\], and brain metastasis) iii) Chemotherapy (including systemic treatment with anticancer therapy and retinoid therapy): 3 weeks (6 weeks for nitrosourea antineoplastic agent and mitomycin C) iv) Antibody-based therapy: 4 weeks v) Small molecule targeted agents: If myelosuppression is not expected, 2 weeks or 5 half-lives, whichever is longer; otherwise, 3 weeks vi) Hormonal treatment: 3 weeks. Previous and concurrent use of hormone replacement therapy, the use of gonadotropin-releasing hormone modulators for prostate cancer, and the use of somatostatin analogs for neuroendocrine tumors are permitted if such therapy has not been changed within 8 weeks before study drug treatment. vii) Pleurodesis: 2 weeks